SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies

mag(2013)

Cited 23|Views15
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined